A COMPREHENSIVE REVIEW ON THE EFFICACY AND SAFETY OF VONOPRAZAN IN THE MANAGEMENT OF GASTRICACID RELATED DISEASES

Priyanka N

doi:10.37022/jpmhs.v9i1.173

Authors

N. Priyanka Associate Professor, Department of Pharmaceutics, St. Ann’s College of Pharmacy

DOI:

https://doi.org/10.37022/jpmhs.v9i1.173

Keywords:

Vonoprazan, potassium competitive, acid blockers, Helicobacter pylori infection Proton, pumpinhibitors, Gastroesophagealreflux diseases, Acid suppression therapy

Abstract

Gastric acid-related diseases, including gastroesophageal reflux disease (GERD), peptic ulcer disease (PUD), and Helicobacter pylori (H. pylori) infection, present significant clinical challenges due to their prevalence and potential for severe complications. Effective management of these conditions is essential for symptom relief, mucosal healing, and prevention of complications. This review aims to evaluate the efficacy and safety of vonoprazan, a novel potassium-competitive acid blocker (P-CAB), in the treatment of gastric acid-related diseases and to compare it with traditional proton pump inhibitors (PPIs). A comprehensive analysis of clinical trials and studies was conducted to assess the effectiveness of vonoprazan in managing GERD, PUD, and H. pylori infection. The safety profile of vonoprazan was also reviewed, and comparisons were made to PPIs and other gastric acid suppressants. Vonoprazan demonstrates superior and more consistent acid suppression than PPIs, resulting in rapid and sustained symptom relief and mucosal healing. Clinical trials have shown its efficacy in treating GERD, PUD, and H. pylori infection, with higher eradication rates for H. pylori when used in combination therapies. The safety profile of vonoprazan is favorable, with fewer adverse effects and drug interactions compared to PPIs. Vonoprazan offers a promising alternative to traditional PPIs for the management of gastric acid-related diseases. Its unique mechanism of action and superior efficacy make it a valuable option for patients requiring effective and reliable acid suppression. Further research is warranted to explore its potential in broader clinical applications and to establish long-term safety data.

Downloads

Download data is not yet available.

References

Narayanan M, Reddy KM, Marsicano E. Peptic ulcer disease and Helicobacter pylori infection. Mo Med. 2018;115(3):219–224. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6140150/

Cleveland Clinic. Peptic ulcer disease [Internet]. Cleveland (OH): Cleveland Clinic; 2024 [cited 2024 Jul]. Available from: https://my.clevelandclinic.org/health/diseases/10350-peptic-ulcer-disease

Clarrett DM, Hachem C. Gastroesophageal reflux disease (GERD). Mo Med. 2018;115(3):214–218. Available from: https://pubmed.ncbi.nlm.nih.gov/30228725/

Gupta A, Shetty S, Mutalik S, et al. Treatment of H. pylori infection and gastric ulcer: need for novel pharmaceutical formulation. Heliyon. 2023;9:e20406. doi:10.1016/j.heliyon.2023.e20406

Sugano K. Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date. Ther Adv Gastroenterol. 2018;11:1756283X17745776. doi:10.1177/1756283X17745776

Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomized, double-blind study. Gut. 2016;65(9):1439–1446. doi:10.1136/gutjnl-2015-311304

Rawla P, Sunkara T, Ofosu A, Gaduputi V. Potassium-competitive acid blockers—are they the next generation of proton pump inhibitors? World J Gastrointest Pharmacol Ther. 2018;9(7):63–68. doi:10.4292/wjgpt.v9.i7.63

Scarpignato C, Leifke E, Smith N, Mulford DJ, Lahu G, Facius A, Howden CW. A population pharmacokinetic model of vonoprazan: evaluating the effects of race, disease status, and other covariates on exposure. J Clin Pharmacol. 2022;62(6):801–811. doi:10.1002/jcph.2019

Sakurai Y, Nishimura A, Kennedy G, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single rising TAK-438 (vonoprazan) doses in healthy male Japanese/non-Japanese subjects. Clin Transl Gastroenterol. 2015;6:e94. doi:10.1038/ctg.2015.18

Kang H, Kim BJ, Choi G, Kim JG. Vonoprazan versus proton pump inhibitors for the management of gastric endoscopic submucosal dissection-induced artificial ulcer: a systematic review with meta-analysis. Medicine (Baltimore). 2019;98(8):e15860. doi:10.1097/MD.0000000000015860